Skip to main content

Mitomycin ophthalmic Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Oct 11, 2022.

Mitomycin ophthalmic is also known as: Mitosol

Mitomycin ophthalmic Pregnancy Warnings

Animal models have revealed evidence of teratogenicity at levels equivalent to the usual human IV dose. There are no controlled data in human pregnancy.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Use is contraindicated.

US FDA pregnancy category: X

Comment: If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Mitomycin ophthalmic Breastfeeding Warnings

Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Mitosol (mitomycin ophthalmic)." Mobius Therapeutics (2012):

References for breastfeeding information

  1. "Product Information. Mitosol (mitomycin ophthalmic)." Mobius Therapeutics (2012):
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network." (2013):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.